GREY:ATBPF - Post by User
Comment by
mstrmndon Oct 16, 2021 1:51pm
244 Views
Post# 34013606
RE:RE:RE:Time to Market for H2S Pipeline
RE:RE:RE:Time to Market for H2S PipelineH2S is not toxic, review the 2a and 2b datasets.
5/42 people with LTE when 3/42 with LTE were expected on a dose ranging AME study does not equal toxicity. There are numerous variables at play and external factors that cannot be ruled out.
The business strategy is clear, data to support short-term or PRN use is there, why go long-term use for OA given AME findings? That's the whole point of doing the AME! Go for the low-hanging fruit and focus on time-to-market.
4 drugs, IP unified, partnership deals in place, $60M on hand and funded to 2024, best time to acquire Antibe is now, waiting longer is risky since H2S clearly has anti-inflammatory + mucosal healing properties and is worth billions - Bayer may loose out and it could go to Chinese or Korean's.
The public market cap is incorrect and there's a significant mismatch with the true value of this company. Canadian exchanges and day-traders have hurt this company significantly.